Form 4 for SKYE Skye Bioscience, Inc.
Accepted 2024-03-01 00:00:00 ET · period of report 2024-02-29 · accession 0001516551-24-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-01 | 2024-02-29 | SKYE | ARSENAULT KAITLYN | CFO | A - Grant | $0.00 | +25.0K | 210.7K | +13% | $0 |
| D | 2024-03-01 | 2024-02-29 | SKYE | ARSENAULT KAITLYN | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-29 | A | A | 25,000 | $0.00 | 210,738 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested. (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-29 | A | A | 75,000 | $0.00 | 75,000 | D | $14.56 · — to 2034-03-01 | 75,000 Common Stock | (F3) The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested. |